New study seeks safer bleeding treatment for hemophilia patients on emicizumab
NCT ID NCT04563520
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study looks at whether a low, personalized dose of aPCC (FEIBA) can safely help blood clot in children and adults with hemophilia A who have inhibitors and are already taking emicizumab. Researchers will measure how well the blood clots after the dose and track any serious side effects. The goal is to find a safer way to manage bleeding episodes in this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.